Ironwood Pharmaceuticals Inc. Watch

EX-10.9

from 10-K 4 pages Ironwood Pharmaceuticals, Inc. Second Amended and Restated 2019 Non-Employee Director Compensation Policy ​

12/34/56

EX-10.1

from 10-Q 10 pages Ironwood Pharmaceuticals, Inc. Amended and Restated 2019 Equity Incentive Plan ​ Restricted Stock Unit Award Agreement

12/34/56

EX-10.1

from 8-K 15 pages Ironwood Pharmaceuticals, Inc. Amended and Restated 2019 Equity Incentive Plan

12/34/56

EX-10.8

from 10-K 4 pages Ironwood Pharmaceuticals, Inc. Amended and Restated 2019 Non-Employee Director Compensation Policy

12/34/56

EX-10.1

from 8-K 8 pages Ironwood Pharmaceuticals, Inc. Executive Severance Agreement

12/34/56

EX-10.1

from 8-K/A 10 pages Ironwood Pharmaceuticals, Inc. Second Amended & Restated Executive Severance Agreement

12/34/56

EX-10.13.1

from 10-K 3 pages Amendment to the Amended and Restated License Agreement

12/34/56

EX-10.5

from 10-Q 10 pages Services Agreement

12/34/56

EX-10.4

from 10-Q 14 pages Dear Halley

12/34/56

EX-10.3

from 10-Q 12 pages Ironwood Pharmaceuticals, Inc. Amended & Restated Executive Severance Agreement

12/34/56

EX-10.2

from 10-Q 6 pages Ironwood Pharmaceuticals, Inc. 2019 Equity Incentive Plan Performance-Based Restricted Stock Unit Award Agreement

12/34/56

EX-10.38

from 10-K 11 pages Jpmorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5jp England Date: August 7, 2019 To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Ma 02142 Attn: Chief Legal Officer From: Jpmorgan Chase Bank, National Association Subject: Partial Terminations of Relevant Transactions Listed on Attached Schedule a and Related Amendments

12/34/56

EX-10.4

from 10-K 10 pages Ironwood Pharmaceuticals, Inc. Amended and Restated 2010 Employee Stock Purchase Plan

12/34/56

EX-10.1

from 8-K 107 pages Certain Confidential Information Contained in This Document, Marked by [**], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Ironwood Pharmaceuticals, Inc. if Publicly Disclosed

12/34/56

EX-10.9

from 8-K 10 pages Jpmorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5jp England Date: August 7, 2019 To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Ma 02142 Attn: Chief Legal Officer From: Jpmorgan Chase Bank, National Association Subject: Partial Terminations of Relevant Transactions Listed on Attached Schedule a and Related Amendments

12/34/56

EX-10.6

from 8-K 32 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Call Option Transaction Entered Into Between Jpmorgan Chase Bank, National Association (“Dealer”) and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

12/34/56

EX-10.5

from 8-K 32 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Call Option Transaction Entered Into Between Jpmorgan Chase Bank, National Association (“Dealer”) and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

12/34/56

EX-10.4

from 8-K 32 pages To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Massachusetts, 02142 Attention: Chief Legal Officer Re: Base Call Option Transaction

12/34/56

EX-10.3

from 8-K 33 pages To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Massachusetts, 02142 Attention: Chief Legal Officer Re: Base Call Option Transaction

12/34/56

EX-10.2

from 8-K 32 pages To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Massachusetts, 02142 Attention: General Counsel Base Call Option Transaction Re

12/34/56